Wall Street Bets Lilly’s GLP-1 Portfolio, Missed $1T
Investors are placing massive bets on Eli Lilly’s GLP-1 drugs, but the push for a $1 trillion opportunity faces medic...
Find beginner-friendly options with understandable use cases and liquidity, plus a simple framework to compare potential investments.
27,615 articlesInvestors are placing massive bets on Eli Lilly’s GLP-1 drugs, but the push for a $1 trillion opportunity faces medic...
Palantir's Alex Karp has reignited the AI debate, arguing that the market overstates near-term gains from frontier mo...
A dramatic decline can hide opportunity. I bought Oracle after it sank from its peak, balancing caution with a clear ...
Blue Owl Capital halted quarterly redemptions for its OBDC II fund and plans distributions funded by asset sales, tri...
Merck stock jumps on a major restructuring, but Reddit sentiment shows growing skepticism as investors weigh Keytruda...
AMD unveils Copilot+-certified Ryzen AI 400 Series desktops, a move aimed at displacing Intel in AI-enabled computing...
KAST announces an $80 million Series A led by QED Investors and Left Lane Capital, valuing the stablecoin fintech at ...
Palantir reports strong government revenue growth while warning that adversaries are increasingly targeting AI data c...
Tesla's stock has traded with unusual calm as the company advances robotaxis and semiconductor initiatives. Early pil...
AI is reshaping the data center landscape, and Marvell is at the center of the action. This piece breaks down why mar...
Could Amazon pull ahead of the broader market? This article builds a disciplined case for why Amazon might outperform...
iQIYI faces a brutal 2026, but a new strategy focused on IP monetization and international growth could unlock sizabl...